Oxytocin

# Oxytocin ## Overview - **Classification**: Uterotonic agent, synthetic posterior pituitary hormone. - **Mechanism**: Stimulates uterine smooth muscle contractions by increasing intracellular calcium; sensitizes myometrial cells to prostaglandins; causes milk ejection reflex. ## Primary Indications 1. **Labor Induction**: To initiate uterine contractions for vaginal delivery. 2. **Labor Augmentation**: To enhance uterine contractions in dysfunctional labor. 3. **Prevention/Treatment of Postpartum Hemorrhage (PPH)**: Management of uterine atony after delivery. 4. **Complete/Incomplete Abortion**: Adjunctive therapy for expulsion of uterine contents. ## Adult Dosing ### Standard Dosing **Labor Induction/Augmentation** - **Dose**: Start **0.5-1 mU/min** IV infusion. - **Frequency**: Increase by **1-2 mU/min** every **15-60 minutes**. - **Route**: Intravenous (IV) infusion via pump, diluted in crystalloid solution. - **Maximum**: Generally **20-40 mU/min**, depending on response and fetal status. - **Special Considerations**: Titrate to achieve adequate labor (2-4 contractions in 10 min); avoid hyperstimulation. **Prevention of Postpartum Hemorrhage (PPH)** - **Dose**: **10 units** IV over **1-2 minutes** (slow push) *after delivery of placenta* OR **20-40 units** in **1000 mL** IV fluid at **20-40 mU/min**. - **Frequency**: Single dose (prevention); continuous infusion for treatment. - **Route**: Intravenous (IV) infusion or slow IV push. - **Duration**: Infusion maintained for several hours postpartum or until hemorrhage controlled. **Treatment of Postpartum Hemorrhage (PPH)** - **Dose**: **10-40 units** in **1000 mL** non-hydrating diluent, infuse at **20-40 mU/min**. - **Frequency**: Continuous infusion, adjust to control uterine atony. - **Route**: Intravenous (IV) infusion. **Complete/Incomplete Abortion** - **Dose**: **10 units** in **500 mL** saline or D5W, infuse at **10-20 mU/min**. - **Frequency**: Continuous infusion. - **Route**: Intravenous (IV) infusion. ### Dose Adjustments - **Renal Impairment**: No specific dose adjustments recommended; use caution due to risk of water intoxication with large doses/prolonged infusion. - **Hepatic Impairment**: No specific dose adjustments recommended. - **Elderly Patients**: Not typically indicated for obstetrical use in elderly patients. ## Pediatric Dosing **Special Note for Pediatric Dosing of Oxytocin:** Oxytocin is not indicated for direct administration to pediatric patients (neonates, infants, children, adolescents) for labor induction/augmentation or prevention/treatment of PPH. Its use is almost exclusively confined to obstetrics in adults. Therefore, no standard pediatric dosing guidelines exist for direct administration. Fetal exposure occurs during maternal administration. ### Neonates (0-28 days) - **Special Notes**: Not indicated for direct administration. Fetal/neonatal effects (e.g., jaundice, arrhythmia) are secondary to maternal administration. ### Infants (1-12 months) - **Special Notes**: Not indicated for direct administration. ### Children (1-12 years) - **Special Notes**: Not indicated for direct administration. ### Adolescents (13-18 years) - **Special Notes**: Not indicated for direct administration. If an adolescent is pregnant, adult obstetrical dosing guidelines apply. ## Safety Information ### Contraindications - **Absolute**: Significant cephalopelvic disproportion (CPD). - **Absolute**: Unfavorable fetal position (e.g., transverse lie). - **Absolute**: Obstetric emergencies requiring surgical intervention (e.g., vasa previa, total placenta previa). - **Absolute**: Fetal distress not amenable to vaginal delivery. - **Absolute**: History of classical uterine incision or uterine surgery. - **Absolute**: Hypersensitivity to oxytocin. ### Common Adverse Effects - **Very Common (>10%)**: Nausea, vomiting. - **Common (1-10%)**: Fetal bradycardia, uterine hypertonicity, uterine spasm, postpartum hemorrhage (paradoxical in some cases). - **Serious but Rare**: Uterine rupture, anaphylaxis, severe fetal distress, fetal death, water intoxication (with large doses/hypotonic fluids), subarachnoid hemorrhage (maternal). ### Key Drug Interactions - **Prostaglandins**: Concurrent use can potentiate oxytocin's uterotonic effect; increased risk of uterine hypertonus/rupture. Avoid simultaneous IV administration; wait **6-12 hours** after prostaglandin E2 vaginal insert removal. - **Vasoconstrictors/Sympathomimetics**: Potentiates pressor effect; severe hypertension can occur (especially with caudal block anesthetics). Monitor BP closely. - **Inhaled Anesthetics (e.g., Halothane)**: May decrease oxytocin's effect on the uterus, potentially requiring higher oxytocin doses. ## Monitoring & Follow-up - **Before Treatment**: Confirm fetal position, assess pelvic adequacy, verify fetal maturity, rule out contraindications. - **During Treatment (Labor)**: Continuous fetal heart rate (FHR) monitoring, uterine contraction pattern (frequency, duration, intensity, resting tone). Maternal vital signs (BP, HR), intake/output (I&O). - **During Treatment (PPH)**: Uterine tone, amount of vaginal bleeding, maternal vital signs (BP, HR), I&O. - **Clinical Signs**: Uterine hyperstimulation (contractions >5 in 10 min or >90 sec duration), signs of fetal distress (late decelerations, bradycardia), signs of water intoxication (headache, confusion, seizures). ## Clinical Pearls - 💡 **Tip 1**: Always administer oxytocin via IV infusion pump to ensure precise dose titration and control. - 💡 **Tip 2**: Closely monitor uterine activity and FHR; discontinue immediately if uterine hyperstimulation or fetal distress occurs. - 💡 **Tip 3**: Use the lowest effective dose; start low and titrate slowly to avoid complications like uterine rupture. - 💡 **Tip 4**: Dilute in isotonic solution (e.g., NS, LR) to minimize risk of water intoxication, especially with prolonged infusions. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.